Courier Capital LLC Reduces Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Courier Capital LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,221 shares of the medical research company’s stock after selling 95 shares during the quarter. Courier Capital LLC’s holdings in Thermo Fisher Scientific were worth $10,202,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Phoenix Holdings Ltd. lifted its holdings in Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after acquiring an additional 1,654 shares during the period. DMC Group LLC lifted its holdings in Thermo Fisher Scientific by 16.5% in the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 84 shares during the period. Montchanin Asset Management LLC lifted its holdings in Thermo Fisher Scientific by 1.1% in the second quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company’s stock valued at $2,374,000 after acquiring an additional 50 shares during the period. Check Capital Management Inc. CA acquired a new position in Thermo Fisher Scientific in the third quarter valued at approximately $219,000. Finally, Tower Bridge Advisors lifted its holdings in Thermo Fisher Scientific by 0.5% in the third quarter. Tower Bridge Advisors now owns 33,046 shares of the medical research company’s stock valued at $16,727,000 after acquiring an additional 155 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.9 %

Shares of NYSE:TMO opened at $579.37 on Thursday. The business has a 50-day moving average price of $564.32 and a 200 day moving average price of $519.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $220.92 billion, a price-to-earnings ratio of 37.50, a PEG ratio of 2.39 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same period last year, the business posted $5.40 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Raymond James upped their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Royal Bank of Canada upped their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. HSBC started coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price target for the company. Finally, Citigroup started coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $599.00.

Insider Activity at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last three months. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.